

Predicting Brinzolamide Ocular Response in Humans Using an Ocular PBPK-PD Modeling and Simulation



SimulationsPlus



Maxime Le Merdy¹, Jim Mullin¹, Ming-Liang Tan², Viera Lukacova¹

1: Simulations Plus, Inc. Research Triangle Park, NC, USA 2: Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD. USA

CONTACT INFORMATION: maxime.lemerdy@simulations-plus.com

PURPOSE

- The development of generic ophthalmic drug products indicated for intraocular pressure (IOP) reduction typically relies on comparative pharmacodynamic (PD) endpoint bioequivalence (BE) studies.
- These studies present challenges for the pharmaceutical industry due to their high costs and limited sensitivity to formulation differences.
- More efficient BE methods are needed to support the development of generic IOP-reducing drug products.
- Ocular physiologically based pharmacokinetic (O-PBPK) modeling is an alternative to support BE assessment of generic ophthalmic drug products.
- There is an increasing number of case studies of O-PBPK models predicting clinical pharmacokinetics (PK) for ophthalmic drug products.
- Brinzolamide (BRI) is a first-line medication for IOP diseases.

OBJECTIVES

- Predict ocular PKs and PDs in rabbits following topical administration of BRI suspension (Azopt®)
- Predict ocular PD response in humans following topical administration of BRI suspension (Azopt®)

METHODS

- All simulations were performed using GastroPlus® (Version 9.9 Simulation Plus Inc., Research Triangle Park, NC, USA). The Ocular Compartmental Absorption and Transit (OCAT™) model was used to build an O-PBPK model for BRI suspension. The OCAT accounts for nasolacrimal drainage, ocular absorption, and distribution in the eye. The PDPlus™ module within GastroPlus was then employed to model the effect of BRI on IOP.
- The O-PBPK model was initially validated using rabbit PK data following BRI topical suspension administration. The PD model describing BRI IOP reduction was validated using rabbit data.
- The O-PBPK-PD model was subsequently applied to predict the observed PD in humans, with physiological parameters adjusted to reflect human physiology. All drug-specific PK and PD parameters, along with their associated variability, were maintained consistent across species.




Figure 1: OCAT model schematic

RESULTS




Figure 2: observed (symbols) and simulated (lines) ocular time courses in NZ rabbits following a single administration of BRI suspension 1%. Abbreviations: NZ: New Zealand; AH: Aqueous Humor; ICB: Iris-ciliary body.




Figure 3: Observed (circles) and simulated (lines) AH concentrations (left) and IOP (right) in NZ rabbits following a single administration of Azopt 1%. The indirect IOP PD model structure is also presented. Abbreviations: NZ: New Zealand; AH: Aqueous Humor; Tr: Transit Compartment; IOP: Intraocular Pressure F_{in} : AH Inflow; F_{us} : AH Uveoscleral Outflow; C_{trab} : AH Trabecular Meshwork Outflow.




Figure 4: O-PBPK-PD model-based prediction of BRI PD effect in humans administered BID or TID. Dots and error bars represent observed data. Lines represent simulations of IOP reduction in 50 virtual patients.

CONCLUSION

- This case study demonstrates the O-PBPK-PD model's capability to describe IOP reduction following BRI administration in rabbits.
- It highlights the model's ability to predict the PD effect in humans using a mechanistic, model-based preclinical-to-clinical translation approach.
- This methodology could support the development of both new and generic ophthalmic drug products by defining a design space for these products.

FUNDING

This project was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of financial assistance award [1U01FD006927] totaling \$500,000 with 100 percent funded by FDA/HHS. **Disclaimer:** This poster reflects the views of the authors and should not be construed to represent the FDA's views or policies.